Inside Rare Disease Week: Taking Advocacy to Capitol Hill (Part 2), Ep. 30
In Part 2 of my Rare Disease Week experience, I take you inside what it’s actually like meeting with lawmakers and their staff on Capitol Hill. I talk about how patient stories influence policy, how advocacy conversations unfold, and why showing up matters for the rare disease community.
Inside Rare Disease Week: Taking Advocacy to Capitol Hill (Part 2), Ep. 30 – The Fine, But Not Fine Podcast
Transcript
Kelly, you look fine, but you’re not fine, and that’s exactly what we’re here to talk about. Welcome to Fine, But Not Fine, the podcast about navigating rare disease, health care battles, and the messy reality of chronic illness. I’m Kelly Paul, and I’ve been living with Mycosis Fungoides since 2015. This is a space for real talk, real experiences, and practical advice, because surviving is one thing, but figuring out how to actually live, that’s the hard part.
In the last episode, I talked about what Rare Disease Week actually looked like, the short meetings, the coordination, the structure. This episode is about what being inside that process clarified for me, because watching federal policy move up close forces you to confront something a little bit uncomfortable. Change does not move at the speed of urgency. It moves at the speed of structure, and if you don’t understand the structure, you will misinterpret the pace.
One of the biggest misconceptions about advocacy is that you go to DC, you meet with someone important, you make your case, and then something magical happens, and that is absolutely not how it works.
You meet with staff, often junior staff, sometimes senior legislative directors, rarely the elected official themselves. They take notes, they ask questions, they request follow up materials, and they flag potential concerns. Then internally, they evaluate, is this already addressed somewhere? What committee would handle this? Is there bipartisan viability and that might change from administration to administration? What’s the funding mechanism? Who opposes this? What’s the trade off? That’s all well before any kind of bill gets anywhere and moves anywhere, right? And that can feel incredibly frustrating when you are advocating on behalf of people who do not have time.
But frustration does not change the architecture; structure governs the pace. It’s not that people don’t care, it’s that the system they’re in has layers. And rare disease advocacy carries urgency. Some of the families I met are facing timelines many of us can’t imagine. There is grief in the room, there is fear, and there is complete exhaustion, and then you sit across from someone who asks about budget scoring, and it can feel incredibly disconnected, but it’s not.
Those questions about funding, about guardrails, about feasibility, are the way the system protects itself from unintended consequences. Emotions, they can open the door. Process decides whether something walks through it, and that tension is real, and sitting in it requires maturity.
There were moments during the week when really powerful stories were shared, some that made the room quiet, you know, and occasionally, unfortunately, those stories stopped there. And it’s not because they weren’t important, it’s because they weren’t translated. And by translating, I mean, if you want change that bridge has to be explicit. You have to be like: this happened. Here is the impact, and here is the legislative lever that addresses it. And without that last piece, that lever, even the most compelling story, just floats. It doesn’t land. And it isn’t a criticism, it’s a reminder, systems require specificity.
And I mentioned this, you know, in the last episode, the meetings aren’t the event, right? The follow up is the event, the email with the data they requested, the clarification on how funding would work, the additional context, at least, you know, for me, around standards of care, that just checking in months later, credibility accumulates slowly. You can’t show up once and expect structural movement. You need to become known as someone who understands both the human impact and the operational realities, and that’s how influence builds. It’s not loud, it’s not instant, but it’s steady.
And this is the nuance. You can believe a system is imperfect. You can believe it’s too slow. You can believe it needs reform, and you still respect that it has rules. If you want to change something, you have got to understand where authority lives. You have to know which committee matters, which agency interprets the rule, where funding is actually allocated, what language makes something viable. Outrage may energize people, but precision moves policy. And this is where our stories, and the organizations like the EveryLife Foundation for Rare Disease or the Cutaneous Lymphoma Foundation, all of these organizations have the professionals that help on that side, and that is really important to what we’re trying to do with advocacy.
You know, one thing I keep thinking about is the caliber of people in those rooms. Rare disease patients aren’t some monolith, right? We are professionals. We are strategic thinkers, we are parents, managing impossible logistics, and we are leaders in our own domains.Living inside a complex healthcare system for years teaches you how systems behave. It teaches you documentation, persistence, appeals, escalation, timing and that perspective isn’t small, it’s informed, and it belongs in policy conversations.
And…Rare Disease Week, no shocker here, did not teach me leadership. It clarified something I already knew but was able to see up close and personal. Large system, they just don’t respond to intensity. They respond to clarity, sustained over time. They respond to people who understand their structure. And they respond to disciplined follow through, whether that system is healthcare, government or business, the mechanics are similar. If you want change, you have to stay in the conversation longer than your initial surge of energy.
Rare Disease Week was not a crescendo moment. It’s a starting line in a marathon. And I think that’s where some people misunderstand. You know, advocacy is not about showing up once. It’s about showing up again and showing up again and showing up again, each time with better questions, better preparation and a clear translation between experience and action. That’s how change at the federal level actually moves.
Thanks for listening to Fine, But Not Fine. If this episode resonated with you, subscribe so you don’t miss what’s next. And if you’ve got a story, question, or just need to vent, reach out. I’d love to hear from you. Until next time, take care and keep on going.